Clinical Trials Logo
  1. Home
  2. Tuberous Sclerosis Complex
  3. NCT05323370

Lymphangioleiomyomatosis, a Study on Cathepsin K — LAM-CAK  

Lymphangioleiomyomatosis Clinical Trial

Official title:
Study of New Potential Biomarkers of Lymphangioleiomyomatosis: Determination of Cathepsin K, Cystatin C, Collagen Telopeptides and Chondroitin Sulfates

Clinical Trial Summary

This is a physiopathological case-control, non-interventional, monocentric study of adult patients with lymphangioleiomyomatosis. The controls are patients followed in neurology at the CHU of Tours for a tuberous sclerosis complex without lymphangioleiomyomatosis, the healthy volunteers are women with neither pulmonary nor renal pathology and recruited at the clinical investigation centre of the CHU of Tours.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05323370
Study type Observational
Source University Hospital, Tours
Contact
Status Completed
Phase
Start date May 31, 2022
Completion date October 30, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT04595513 - Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants Phase 1/Phase 2
Completed NCT02687633 - Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex N/A
Completed NCT02201212 - Everolimus for Cancer With TSC1 or TSC2 Mutation Phase 2
Completed NCT01767779 - Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
Recruiting NCT05104983 - Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study Phase 2
Recruiting NCT02098759 - Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex N/A
Recruiting NCT01730209 - Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex Phase 2/Phase 3
Recruiting NCT03356769 - Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex Phase 2
Recruiting NCT04987463 - Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants Phase 2/Phase 3
Enrolling by invitation NCT05604170 - Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy Phase 3
Completed NCT03276195 - Studies in Patients With Tuberous Sclerosis Complex
Recruiting NCT05059327 - Basimglurant in Children, Adolescents, and Young Adults With TSC Phase 2
Completed NCT02061397 - Safety of Simvastatin in LAM and TSC Phase 1/Phase 2
Active, not recruiting NCT04112537 - Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
Active, not recruiting NCT02962414 - Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment Phase 3
Active, not recruiting NCT05495425 - Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC Phase 3
Recruiting NCT05044819 - Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution Phase 4
Completed NCT01929642 - Rapalogues for Autism Phenotype in TSC: A Feasibility Study Phase 2
Recruiting NCT06160310 - Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry (TSC-LAM Registry)
Recruiting NCT05534672 - Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex Phase 3